Lamivudine-resistant HIV_M184V is durably suppressed with dolutegravir plus lamivudine dual therapy in humanised mice

J Glob Antimicrob Resist. 2020 Mar:20:316-317. doi: 10.1016/j.jgar.2020.01.018. Epub 2020 Feb 13.

Authors

Sandra Medina-Moreno¹, Juan C Zapata¹, Fatah Kashanchi², Nhut M Le¹, Said Hassounah³, Thibault Mesplede³, Maureen Oliveira³, Charles C Davis¹, Alonso Heredia⁴

Affiliations

¹ Institute of Human Virology, University of Maryland School of Medicine, 725 W. Lombard St., Baltimore, MD 21201, USA.
² Laboratory of Molecular Virology, George Mason University, Manassas, VA, USA.
³ McGill University AIDS Centre/Lady Davis Institute, Montréal, Quebec, Canada.
⁴ Institute of Human Virology, University of Maryland School of Medicine, 725 W. Lombard St., Baltimore, MD 21201, USA. Electronic address: aheredia@ihv.umaryland.edu.

PMID: 32061877
DOI: 10.1016/j.jgar.2020.01.018

No abstract available

Publication types

Comparative Study
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Administration, Oral
Animals
Disease Models, Animal
Drug Combinations
HIV / drug effects
HIV / genetics*
HIV Infections / drug therapy*
Heterocyclic Compounds, 3-Ring / administration & dosage*
Heterocyclic Compounds, 3-Ring / pharmacology
Humans
Lamivudine / administration & dosage*
Lamivudine / pharmacology
Mice
Mutation
Oxazines / administration & dosage*
Oxazines / pharmacology
Piperazines / administration & dosage*
Piperazines / pharmacology
Pyridones / administration & dosage*
Pyridones / pharmacology
Treatment Outcome

Substances

Drug Combinations
Heterocyclic Compounds, 3-Ring
Oxazines
Piperazines
Pyridones
Lamivudine
dolutegravir